MARKET

NMTR

NMTR

9 Meters Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7601
+0.0054
+0.72%
Opening 10:25 01/27 EST
OPEN
0.7500
PREV CLOSE
0.7547
HIGH
0.7701
LOW
0.7466
VOLUME
133.51K
TURNOVER
--
52 WEEK HIGH
2.260
52 WEEK LOW
0.7185
MARKET CAP
194.33M
P/E (TTM)
-5.3191
1D
5D
1M
3M
1Y
5Y
9 meters Bio secures new U.S. patent for NM-102 + immune checkpoint inhibitors
9 Meters Biopharma (NASDAQ:NMTR) has received notice from the USPTO that U.S. Patent Application No. 17/239,056 is allowed. The patent demonstrates that NM-102, which can prevent disruption of and/or restore
Seekingalpha · 3d ago
BRIEF-9 Meters Biopharma Announces Allowance Of Patent For NM-102 In Combination With Immune Checkpoint Inhibitors
reuters.com · 3d ago
9 Meters Biopharma's Patent for NM-102 Approved
The patent demonstrates that NM-102, which can prevent disruption of and/or restore the functional integrity of the ileal and/or colonic intestinal barrier, can improve the benefit of immune checkpoint inhibitors (ICIs)
Benzinga · 3d ago
9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
RALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from th...
ACCESSWIRE · 3d ago
9 Meters Biopharma Gets US Notice of Allowance for Patent Covering NM-102 Cancer Therapy
MT Newswires · 3d ago
Raleigh public company adds former Biogen exec to suite
A relatively new biopharmaceutical company in Raleigh has added a new name to its C-suite. 9 Meters Biopharma (Nasdaq: NMTR) has appointed Bethany Sensenig to be chief financial officer. Sensenig is joining the clinical-stage company, which is focused on...
American City Business Journals · 5d ago
BRIEF-9 Meters Biopharma Inc - Appoints Bethany Sensenig As CFO
reuters.com · 01/18 13:22
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pion...
ACCESSWIRE · 01/18 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NMTR. Analyze the recent business situations of 9 Meters Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NMTR stock price target is 5.25 with a high estimate of 6.00 and a low estimate of 5.00.
High6.00
Average5.25
Low5.00
Current 0.7601
EPS
Actual
Estimate
-0.04-0.03-0.02-0.01
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 110
Institutional Holdings: 72.78M
% Owned: 28.47%
Shares Outstanding: 255.67M
TypeInstitutionsShares
Increased
28
4.63M
New
18
4.70M
Decreased
21
8.33M
Sold Out
11
2.75M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+1.42%
Key Executives
Non-Executive Chairman/Independent Director
Mark Sirgo
President/Chief Executive Officer/Director
John Temperato
Chief Financial Officer
Bethany Sensenig
Other
Sarah Liu
Independent Director
Michael Constantino
Independent Director
Lorin Johnson
Independent Director
Michael Rice
Independent Director
Samantha Ventimiglia
No Data
About NMTR
9 Meters Biopharma, Inc., formerly Innovate Biopharmaceuticals, Inc., is a gastrointestinal platform company. The Company is focused on developing treatments for patients with rare disorders and unmet needs. Its pipeline includes drug candidates for short bowel syndrome and celiac disease. Its pipeline includes NM-002, Larazotide, NM-003 and NM-004. NM-002 is a long-acting injectable GLP-1 analogue for short bowel syndrome (SBS). Larazotide is an orally administered, gut-restricted tight-junction regulator for celiac disease. NM-003 is a GLP-2 analogue, under orphan indication selection. NM -004 is an immunomodulator, granted pediatric orphan designation in ulcerative colitis.

Webull offers kinds of 9 Meters Biopharma Inc stock information, including NASDAQ:NMTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NMTR stock methods without spending real money on the virtual paper trading platform.